Novome Biotechnologies
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $43.5M
Overview
A synthetic biology company developing engineered microbial therapeutics for precise, localized treatment of chronic gut diseases.
Metabolic DisordersGastroenterologyNephrology
Technology Platform
The GENIE platform engineers bacterial strains to colonize the gut in a controlled manner using specific dietary polysaccharides and produce therapeutic proteins.
Funding History
1Total raised:$43.5M
PIPE$43.5M
Opportunities
Platform could address a wide range of chronic diseases by enabling localized, sustained drug production in the gut.
Risk Factors
Clinical and regulatory risks are high for a novel, living therapeutic, including long-term safety and manufacturing complexity.
Competitive Landscape
Operates in the engineered live biotherapeutic product (eLBP) space, competing with companies like Synlogic and Vedanta Biosciences.